NCT02066181 2023-06-07
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
National Cancer Institute (NCI)
Phase 3 Completed
Clinical Trials
20 trialsNCT02050919 2022-03-21
Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00822848 2018-09-07
Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma
OHSU Knight Cancer Institute
Phase 1 Completed
NCT00335764 2018-07-02
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00621686 2018-05-08
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00703638 2017-11-29
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT01005797 2017-03-03
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
Medical University of South Carolina
Phase 1 Completed
NCT00238121 2015-11-20
Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00837148 2015-11-20
Sorafenib and Dacarbazine in Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01804374 2015-06-17
SERIO
Italian Sarcoma Group
Phase 2 Completed
NCT01518413 2015-02-27
Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
Children's National Research Institute
Phase 1 Completed
NCT00093613 2014-05-30
Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00245102 2014-05-23
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00217620 2014-05-15
S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas
National Cancer Institute (NCI)
Phase 2 Completed
NCT00330421 2014-04-30
Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)
National Cancer Institute (NCI)
Phase 2 Completed
NCT00597493 2013-06-24
Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM
Duke University
Phase 2 Completed
NCT00864032 2013-04-10
Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall
University of California, Davis
Phase 1/2 Completed
NCT00889057 2013-03-28
Sorafenib in Relapsed High Grade Osteosarcoma
Italian Sarcoma Group
Phase 2 Completed
NCT01091207 2012-01-20
Sorafenib for Imatinib/Sunitinib-failed GIST
Samsung Medical Center
Phase 2 Completed
NCT00406601 2010-09-02
BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas
Istituto Clinico Humanitas
Phase 2 Completed